Inclusion Criteria:

          -  In good health as evidenced by medical history or diagnosed with relapsed or
             chemotherapy-refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B
             cell lymphoma (PMLBCL), transformed follicular lymphoma (TFL) and high-grade B cell
             lymphoma (HGBCL). Patients must be under consideration for treatment with any
             CD19-targeted CAR T cell therapy, per institutional standards. Patients undergoing
             active vital organ testing with a planned apheresis date for CAR T cell therapy may be
             considered eligible.

          -  Signed informed consent form in accordance with institutional and federal law policies

          -  Stated willingness to comply with all study procedures and availability for the
             duration of the study

          -  Male or female, age over 18

          -  For females of reproductive potential: use of highly effective contraception for at
             least 1 month prior to screening and agreement to use such a method during study
             participation

        Exclusion Criteria:

          -  Pregnant or lactating woman, as evaluated by serum testing within 2 weeks of
             administration of the first vaccine. Only women of childbearing potential will undergo
             serum/urine pregnancy testing. A woman will be considered of childbearing potential
             unless she is status-post hysterectomy or tubal ligation or without menstrual periods
             in the preceding 12 months.

          -  Common variable immunodeficiency or other inherited systemic immunodeficiency syndrome

          -  History of severe allergy (e.g., anaphylaxis) to any component of pneumococcal
             conjugate vaccine 7 valent (PCV7), PCV13, or any diphtheria-toxoid containing vaccine.

          -  Inclusion on a separate trial in which patients may be randomized or otherwise started
             on maintenance chemotherapies within the first 3 months of CD19-targeted CAR T cell
             therapy

          -  Patients with significant psychiatric illness likely to affect compliance, as
             determined by the treating physician

          -  Active or uncontrolled infections

          -  Platelet count <10,000 cells/microliter

          -  Lymphocyte count <200 cells/microliter

          -  Intervenous immunoglobulin (IVIG) administration within one month of planned apheresis
             for collection for CD19-targeted CAR T cell manufacture

          -  History of PCV13 administration within one month of planned apheresis for collection
             for CD19-targeted CAR T cell manufacture